Biogen Inc. has disclosed uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists with improved brain penetration reported to be useful for the treatment of multiple sclerosis.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果